-
Signature
-
/s/ Randall Moreadith
-
Issuer symbol
-
SER
-
Transactions as of
-
20 Jan 2026
-
Net transactions value
-
-$11,900
-
Form type
-
4
-
Filing time
-
21 Jan 2026, 19:17:14 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Moreadith Randall |
Chief Scientific Officer |
601 GENOME WAY, SUITE 2001, HUNTSVILLE |
/s/ Randall Moreadith |
21 Jan 2026 |
0001301120 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
SER |
Common Stock |
Options Exercise |
$120 |
+2,000 |
|
$0.0600 |
2,000 |
20 Jan 2026 |
Direct |
|
| transaction |
SER |
Common Stock |
Sale |
$6,140 |
-2,000 |
-100% |
$3.07 |
0 |
20 Jan 2026 |
Direct |
|
| transaction |
SER |
Common Stock |
Options Exercise |
$120 |
+2,000 |
|
$0.0600 |
2,000 |
21 Jan 2026 |
Direct |
|
| transaction |
SER |
Common Stock |
Sale |
$6,000 |
-2,000 |
-100% |
$3.00 |
0 |
21 Jan 2026 |
Direct |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
SER |
Stock Option (right to buy) |
Options Exercise |
$0 |
-2,000 |
-0.6% |
$0.000000 |
330,686 |
20 Jan 2026 |
Common Stock |
2,000 |
$0.0600 |
Direct |
F1 |
| transaction |
SER |
Stock Option (right to buy) |
Options Exercise |
$0 |
-2,000 |
-0.6% |
$0.000000 |
328,686 |
21 Jan 2026 |
Common Stock |
2,000 |
$0.0600 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: